GH Secretagogues
GHRP-2
← Back to Library
Limited / unverified FDA safety flag Limited / unverified GH Axis
Educational reference only. Read the full disclaimer.
The protocols below are not automatically an FDA-approved or clinically verified regimen unless
explicitly marked as label-verified or clinical-trial above.
Overview
Route(s): Subcutaneous
Typical vial sizes: 5, 10 mg
Dosing window: Pre-Bed Fasted
Receptor / target: GHS-R1a
Properties: GH Secretagogue
Pre-mixed: No
Unverified protocol notes
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-2 | 100mcg 1x Daily | Administered pre-bed, completely fasted. |
| Weeks 3-4 | 150mcg 1x Daily | Administered pre-bed, completely fasted. |
| Weeks 5-8 | 200mcg 1x Daily | Administered pre-bed, completely fasted. |
| Weeks 9-12 | 250-300mcg 1x Daily | Administered pre-bed, completely fasted. |
Unverified protocol note; not label dosing unless graded otherwise on this page.
Alternative 1: High Frequency
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-12 | 100mcg 3x daily | Morning, Post-Workout, Pre-Bed. |
Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Alternative 2: Anti-Aging Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-12 | 150mcg 1x Daily | Take at bedtime. |
Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Protocol logic check
Protocol context: GH-axis protocols are not 'more is better.' The logic is pulse quality, recovery time, IGF-1/glucose monitoring, and avoiding receptor desensitization, edema, appetite spikes, numbness, or blood-pressure strain. Entry context: target (GHS-R1a); route Subcutaneous; timing Pre-Bed Fasted. Limited-evidence dosing tables are hypotheses, not recommendations. FDA/safety flags lower confidence and raise the evidence bar for any claimed benefit. Compatibility is conditional: a reasonable solo compound can become inappropriate once a contraindicated partner is added. GH-axis stacking should be filtered for total IGF-1/glucose burden, not just expected synergy.
Independent evidence
Independent safety notes: FDA lists injectable/nasal GHRP-2 in category 2 with immunogenicity/impurity concerns and serious adverse event reports.
Regulatory status: unapproved or compounded peptide with FDA safety risk flag
Storage
No independently verified storage guidance found. Treat any unverified storage claim as unverified, and see the general storage guidance in the FAQ.
Contraindications (limited evidence)
- Active malignancy: GH/IGF-1 elevation may accelerate tumor cell proliferation. Limited / unverified
- History of pituitary tumor or pituitary adenoma: unpredictable response to GHS-R1a stimulation. Limited / unverified
- Uncontrolled diabetes mellitus or severe insulin resistance: GH elevation worsens glycemic control. Limited / unverified
- Diabetic ketoacidosis. Limited / unverified
- Active or history of prolactinoma: GHRP-2 elevates prolactin via GHS-R1a activation on lactotrophs. Limited / unverified
- Hypersensitivity or known allergy to GHRP-2 or excipients. Limited / unverified
- Concurrent use with ipamorelin or GHRP-6: receptor competition at GHS-R1a; do not stack two GHRPs. Limited / unverified
- Concurrent use with HGH 191aa: additive and redundant GH axis overstimulation. Limited / unverified
- Concomitant high-dose glucocorticoid therapy: attenuates pituitary GH response and amplifies cortisol load from GHRP stimulation. Limited / unverified
- Concomitant insulin therapy without adjustment: GH-mediated insulin resistance may destabilize glycemic control. Limited / unverified
- High baseline cortisol or adrenal stress states: GHRP-2's cortisol-elevating effect adds further HPA axis load. Limited / unverified
- Pregnancy: safety not established. Limited / unverified
- Breastfeeding: safety not established. Limited / unverified
- Pediatric use with closed growth plates. Limited / unverified
Side effects (limited evidence)
- Acute hunger and appetite stimulation: moderate; centrally mediated via ghrelin pathway NPY/AgRP activation; less intense than GHRP-6 but more than ipamorelin; begins within 20-30 minutes of injection. Limited / unverified
- Mild cortisol elevation: transient, typically returns to baseline within 2-4 hours post-injection; approximately 40% less than GHRP-6 at equipotent doses; monitor in subjects with baseline cortisol concerns. Limited / unverified
- Mild prolactin elevation: transient; similar pattern to cortisol response; lower than GHRP-6 and hexarelin. Limited / unverified
- Head rush and transient facial flushing: acute vasodilation from GH pulse; resolves within 15-30 minutes. Limited / unverified
- Water retention and peripheral edema: GH-mediated sodium and fluid retention; common in first 2-4 weeks. Limited / unverified
- Joint stiffness: GH-related periarticular fluid accumulation. Limited / unverified
- Tingling or numbness in extremities: paresthesia; GH-related fluid shifts. Limited / unverified
- Vivid dreams: GH elevation during nocturnal sleep. Limited / unverified
- Lethargy and mild fatigue post-injection: associated with the acute GH pulse. Limited / unverified
- Headache: vasodilation-related; typically early in the protocol. Limited / unverified
- Injection site irritation: redness, swelling, or pain at subcutaneous administration site. Limited / unverified
- Mild transient hypoglycemia: possible when dosing fasted, particularly with GHRH analog co-administration. Limited / unverified
- Insulin resistance: with extended high-dose protocols; GH elevation progressively reduces insulin sensitivity; monitor fasting glucose. Limited / unverified
- Decreased efficacy of corticosteroid therapy: GHRP-2 can blunt glucocorticoid response. Limited / unverified
Compatibility
The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
Reported contraindicated combinations: